US5266480A
(en)
*
|
1986-04-18 |
1993-11-30 |
Advanced Tissue Sciences, Inc. |
Three-dimensional skin culture system
|
CA1310924C
(fr)
*
|
1986-04-24 |
1992-12-01 |
Francis P. Mccormick |
Systeme d'administration d'un medicament a l'aide de particules infectieuses
|
US5219740A
(en)
*
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US6048729A
(en)
*
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
ES2094720T3
(es)
*
|
1987-05-01 |
1997-02-01 |
Gen Hospital Corp |
Implantacion transcariotica.
|
ATE117375T1
(de)
*
|
1987-09-11 |
1995-02-15 |
Whitehead Biomedical Inst |
Transduktionsveränderte fibroblasten und ihre anwendung.
|
US6140111A
(en)
*
|
1987-12-11 |
2000-10-31 |
Whitehead Institute For Biomedical Research |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
US6544771B1
(en)
|
1987-12-11 |
2003-04-08 |
Cell Genesys, Inc. |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
JP2914692B2
(ja)
*
|
1987-12-11 |
1999-07-05 |
ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ |
内皮細胞の遺伝子修飾
|
US5580776A
(en)
*
|
1988-02-05 |
1996-12-03 |
Howard Hughes Medical Institute |
Modified hepatocytes and uses therefor
|
EP0400047B1
(fr)
*
|
1988-02-05 |
1997-04-23 |
Whitehead Institute For Biomedical Research |
Hepatocytes modifies et leurs utilisations
|
US5716826A
(en)
*
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
US6133029A
(en)
|
1988-03-21 |
2000-10-17 |
Chiron Corporation |
Replication defective viral vectors for infecting human cells
|
ZA892518B
(en)
*
|
1988-04-08 |
1989-12-27 |
Intracel Corp |
Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells
|
US6645942B1
(en)
|
1988-04-28 |
2003-11-11 |
The Salk Institute For Biological Studies |
Somatic cell gene therapy
|
AU4061989A
(en)
*
|
1988-08-04 |
1990-03-05 |
Carolyn C. Compton |
Transplanting cultured epithelial cells with a desired phenotypic trait
|
ATE174514T1
(de)
*
|
1989-01-23 |
1999-01-15 |
Chiron Corp |
Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
|
US5605821A
(en)
*
|
1989-03-08 |
1997-02-25 |
Board Of Regents Of The University Of Oklahoma |
Expression control sequences of the P-selectin gene
|
US5624824A
(en)
*
|
1989-03-24 |
1997-04-29 |
Yale University |
Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US5091173A
(en)
*
|
1989-06-29 |
1992-02-25 |
The University Of Dundee |
Hair growth composition
|
SG49267A1
(en)
|
1989-08-14 |
1998-05-18 |
Photogenesis Inc |
Surgical instrument and cell isolation and transplantation
|
US6514238B1
(en)
*
|
1989-08-14 |
2003-02-04 |
Photogenesis, Inc. |
Method for preparation and transplantation of volute grafts and surgical instrument therefor
|
JP2533693B2
(ja)
*
|
1989-08-14 |
1996-09-11 |
フォトジェネシス インコーポレイテッド |
外科器具および細胞分離および移植術
|
US5817075A
(en)
*
|
1989-08-14 |
1998-10-06 |
Photogenesis, Inc. |
Method for preparation and transplantation of planar implants and surgical instrument therefor
|
US6984487B1
(en)
|
1989-08-22 |
2006-01-10 |
Hsc Research Development Corporation |
Cystic fibrosis gene
|
US5863770A
(en)
*
|
1989-08-22 |
1999-01-26 |
Hsc Research And Development Limited Partnership |
Stable meterologous propagation of CFTR protein variant cDNA
|
US5585362A
(en)
*
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
US5240846A
(en)
*
|
1989-08-22 |
1993-08-31 |
The Regents Of The University Of Michigan |
Gene therapy vector for cystic fibrosis
|
US5543399A
(en)
*
|
1989-08-22 |
1996-08-06 |
Hsc Research & Development Limited Partnership |
Cystic fibrosis transmembrane conductance regulator (CFTR) protein
|
US6063913A
(en)
*
|
1989-08-22 |
2000-05-16 |
Hsc Research And Development Limited Partnership |
Stable heterologous propagation CFTR protein variant cDNA
|
ATE212672T1
(de)
*
|
1989-10-24 |
2002-02-15 |
Chiron Corp |
System zur freisetzung von infektiösen proteinen
|
US5423778A
(en)
*
|
1989-12-14 |
1995-06-13 |
Elof Eriksson |
System and method for transplantation of cells
|
US5697901A
(en)
*
|
1989-12-14 |
1997-12-16 |
Elof Eriksson |
Gene delivery by microneedle injection
|
US5661132A
(en)
*
|
1989-12-14 |
1997-08-26 |
Auragen, Inc. |
Wound healing
|
US6090790A
(en)
*
|
1989-12-14 |
2000-07-18 |
Eriksson; Elof |
Gene delivery by microneedle injection
|
DE69132616T2
(de)
*
|
1990-01-12 |
2002-02-21 |
Hsc Res Dev Corp |
Introns und exons des gens für cystische fibrose sowie mutationen an mehreren stellen des gens
|
US5068315A
(en)
*
|
1990-04-12 |
1991-11-26 |
University Of Dundee |
Composition for the regulation of hair growth
|
AU7746091A
(en)
*
|
1990-04-17 |
1991-11-11 |
Pherin Corporation |
Methods of tissue implantation
|
US5817491A
(en)
*
|
1990-09-21 |
1998-10-06 |
The Regents Of The University Of California |
VSV G pseusdotyped retroviral vectors
|
DK0506945T3
(da)
*
|
1990-10-25 |
1999-04-26 |
Clague Pitman Hodgson |
Fremgangsmåde til genoverførsel under anvendelse af retrotransposoner
|
US6027722A
(en)
*
|
1990-10-25 |
2000-02-22 |
Nature Technology Corporation |
Vectors for gene transfer
|
US5849686A
(en)
*
|
1991-03-11 |
1998-12-15 |
Creative Biomolecules, Inc. |
Morphogen-induced liver regeneration
|
PT101031B
(pt)
|
1991-11-05 |
2002-07-31 |
Transkaryotic Therapies Inc |
Processo para o fornecimento de proteinas por terapia genetica
|
US6063630A
(en)
*
|
1991-11-05 |
2000-05-16 |
Transkaryotic Therapies, Inc. |
Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
|
US6270989B1
(en)
|
1991-11-05 |
2001-08-07 |
Transkaryotic Therapies, Inc. |
Protein production and delivery
|
US5968502A
(en)
|
1991-11-05 |
1999-10-19 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US6054288A
(en)
*
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6692737B1
(en)
|
1991-11-05 |
2004-02-17 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US5641670A
(en)
*
|
1991-11-05 |
1997-06-24 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US6297048B1
(en)
|
1992-02-04 |
2001-10-02 |
Chiron Corporation |
Hepatitis therapeutics
|
US6045791A
(en)
*
|
1992-03-06 |
2000-04-04 |
Photogenesis, Inc. |
Retinal pigment epithelium transplantation
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
JP3973050B2
(ja)
|
1992-09-16 |
2007-09-05 |
キュリス,インコーポレイテッド |
モルフォゲン誘発性肝再生
|
US5380747A
(en)
*
|
1992-10-30 |
1995-01-10 |
Emory University |
Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
|
US5807884A
(en)
*
|
1992-10-30 |
1998-09-15 |
Emory University |
Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
|
EP0688358A4
(fr)
|
1993-03-12 |
1997-10-01 |
Univ Creighton |
Vecteurs ameliores en therapie genique
|
DE69431106T2
(de)
*
|
1993-05-10 |
2003-05-08 |
Univ Michigan Ann Arbor |
Gentransfer zu den pankreatischen epithelzellen
|
US5591625A
(en)
*
|
1993-11-24 |
1997-01-07 |
Case Western Reserve University |
Transduced mesenchymal stem cells
|
US5869248A
(en)
*
|
1994-03-07 |
1999-02-09 |
Yale University |
Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
|
US5498537A
(en)
*
|
1994-03-09 |
1996-03-12 |
Cellco, Inc. |
Serum-free production of packaged viral vector
|
IL113052A0
(en)
|
1994-03-23 |
1995-06-29 |
Rhone Poulenc Rorer Sa |
Recombinant viruses, their preparation and their use in gene therapy
|
US5850002A
(en)
*
|
1994-04-20 |
1998-12-15 |
Washington University |
Animal models for loss and gain of Hox11 function
|
US6150137A
(en)
|
1994-05-27 |
2000-11-21 |
Ariad Pharmaceuticals, Inc. |
Immunosuppressant target proteins
|
US5888814A
(en)
*
|
1994-06-06 |
1999-03-30 |
Chiron Corporation |
Recombinant host cells encoding TNF proteins
|
US5962322A
(en)
*
|
1996-11-15 |
1999-10-05 |
Massachusetts Institute Of Technology |
Methods for modulation of cholesterol transport
|
US7078511B1
(en)
|
1994-06-23 |
2006-07-18 |
Massachusette Institute Of Technology |
Class BI and CI scavenger receptors
|
US5695993A
(en)
*
|
1994-08-12 |
1997-12-09 |
Oklahoma Medical Research Foundation |
Cloning and regulation of an endothelial cell protein C/activated protein C receptor
|
US5898066A
(en)
*
|
1994-08-26 |
1999-04-27 |
Children's Medical Center Corporation |
Trophic factors for central nervous system regeneration
|
US5683873A
(en)
*
|
1995-01-13 |
1997-11-04 |
Innovir Laboratories, Inc. |
EGS-mediated inactivation of target RNA
|
US6057153A
(en)
*
|
1995-01-13 |
2000-05-02 |
Yale University |
Stabilized external guide sequences
|
US5868728A
(en)
*
|
1995-02-28 |
1999-02-09 |
Photogenesis, Inc. |
Medical linear actuator for surgical delivery, manipulation, and extraction
|
US7422574B2
(en)
|
1995-05-19 |
2008-09-09 |
Applied Tissue Technologies, Llc |
Microseeding device for gene delivery by microneedle injection
|
US20030190753A1
(en)
*
|
1995-11-09 |
2003-10-09 |
Nature Technology Corporation |
Vectors for gene transfer
|
US5925333A
(en)
*
|
1995-11-15 |
1999-07-20 |
Massachusetts Institute Of Technology |
Methods for modulation of lipid uptake
|
US6689757B1
(en)
|
1996-02-12 |
2004-02-10 |
M.L. Laboratories Plc |
Methods for vaccination and vaccines therefor
|
US5877162A
(en)
*
|
1996-03-14 |
1999-03-02 |
Innovir Laboratories, Inc. |
Short external guide sequences
|
US6027721A
(en)
*
|
1996-05-20 |
2000-02-22 |
Cytotherapeutics, Inc. |
Device and method for encapsulated gene therapy
|
US5945100A
(en)
*
|
1996-07-31 |
1999-08-31 |
Fbp Corporation |
Tumor delivery vehicles
|
US5948681A
(en)
*
|
1996-08-14 |
1999-09-07 |
Children's Hospital Of Philadelphia |
Non-viral vehicles for use in gene transfer
|
US6108637A
(en)
|
1996-09-03 |
2000-08-22 |
Nielsen Media Research, Inc. |
Content display monitor
|
DE69732847T2
(de)
|
1996-11-08 |
2006-04-13 |
Oklahoma Medical Research Foundation, Oklahoma |
Endothel-spezifischer expression unter einfluss von epcr kontrollelementen
|
CA2205076A1
(fr)
|
1997-05-14 |
1998-11-14 |
Jim Hu |
Cassettes pour l'expression episomale en therapie genique
|
US6635623B1
(en)
|
1997-06-13 |
2003-10-21 |
Baylor College Of Medicine |
Lipoproteins as nucleic acid vectors
|
US20050096288A1
(en)
*
|
1997-06-13 |
2005-05-05 |
Aragene, Inc. |
Lipoproteins as nucleic acid vectors
|
US6096303A
(en)
*
|
1997-07-31 |
2000-08-01 |
Medical College Of Georgia Research Institute, Inc. |
Method to enhance treatment of cystic tumors
|
WO1999011288A1
(fr)
*
|
1997-09-05 |
1999-03-11 |
Massachusetts Institute Of Technology |
Antagoniste de sr-bi et son utilisation comme contraceptif et pour le traitement de la surproduction de steroides
|
AU1628599A
(en)
|
1997-12-05 |
1999-06-28 |
Medical College Of Georgia Research Institute, Inc. |
Regulation of t cell-mediated immunity by tryptophan
|
US6441158B1
(en)
|
1997-12-31 |
2002-08-27 |
Medical College Of Georgia Research Institute, Inc. |
Oligomers that bind to ku protein
|
CA2245224A1
(fr)
*
|
1998-08-14 |
2000-02-14 |
Jiang-Hong Giong |
Antagonistes du recepteur de la chimiokine et chimiotherapie
|
AU762472B2
(en)
*
|
1998-03-13 |
2003-06-26 |
University Of British Columbia, The |
Therapeutic chemokine receptor antagonists
|
CA2305787A1
(fr)
*
|
2000-05-09 |
2001-11-09 |
The University Of British Columbia |
Traitement antagoniste cxcr4 de cellules hematopoietiques
|
CA2344653A1
(fr)
|
1998-09-29 |
2000-04-06 |
Gamida Cell Ltd. |
Procedes de regulation de la proliferation et de la differentiation de cellules souches et precurseurs
|
EP1119625B1
(fr)
|
1998-10-07 |
2005-06-29 |
Medical College Of Georgia Research Institute, Inc. |
Peptide glucodependant insulinotrope utilise comme hormone osteotrope
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
WO2000051628A2
(fr)
*
|
1999-03-03 |
2000-09-08 |
Biogen, Inc. |
Methodes de modulation du metabolisme et du stockage lipidiques
|
WO2000053743A1
(fr)
|
1999-03-12 |
2000-09-14 |
Gpc Biotech, Inc. |
Methodes et reactifs permettant d'identifier des elements genetiques synthetiques
|
US6328762B1
(en)
*
|
1999-04-27 |
2001-12-11 |
Sulzer Biologics, Inc. |
Prosthetic grafts
|
US7396905B1
(en)
|
1999-05-21 |
2008-07-08 |
Mckeon Frank |
Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
|
AUPQ206399A0
(en)
|
1999-08-06 |
1999-08-26 |
Imr Worldwide Pty Ltd. |
Network user measurement system and method
|
DE10100586C1
(de)
*
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US6951839B1
(en)
|
1999-11-30 |
2005-10-04 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
US8168178B2
(en)
*
|
1999-11-30 |
2012-05-01 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
PT1254169E
(pt)
|
1999-12-30 |
2007-08-21 |
Harvard College |
''métodos relativos à modulação da actividade do subconjunto de células th2 por modulação da actividade de xbp-1''
|
AU2001250922A1
(en)
*
|
2000-03-22 |
2001-10-03 |
Board Of Trustees Of The University Of Arkansas |
Secreting products from skin by adeno-associated virus (aav) gene transfer
|
US7378098B2
(en)
*
|
2000-04-12 |
2008-05-27 |
The University Of British Columbia |
CXC chemokine receptor 4 agonist peptides
|
US20050059584A1
(en)
*
|
2002-08-16 |
2005-03-17 |
Ahmed Merzouk |
Novel chemokine mimetics synthesis and their use
|
CA2335109A1
(fr)
*
|
2000-04-12 |
2001-10-12 |
Chemokine Therapeutics Corporation |
Traitement de cellules hematopoietiques avec des agonistes du cxcr4
|
US7368425B2
(en)
*
|
2006-03-24 |
2008-05-06 |
Chemokine Therapeutics Corp. |
Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
|
EP1702983A3
(fr)
|
2000-04-13 |
2007-01-10 |
Medical University of South Carolina |
Agents toxiques, ribozymes, ADNzymes et oligonucléotides antisens spécifiques des tissus et des pathogènes et procédé d'utilisation associé
|
ATE437944T1
(de)
*
|
2000-04-28 |
2009-08-15 |
Asklepios Biopharmaceutical In |
Für das dystrophin-minigen kodierende dna- sequenzen und verfahren zu deren verwendung
|
CA2419159A1
(fr)
*
|
2000-08-11 |
2002-02-21 |
Agilix Corporation |
Systemes de detection ultrasensibles
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
EP1326892A2
(fr)
|
2000-10-12 |
2003-07-16 |
University of Rochester |
Compositions inhibant la proliferation de cellules cancereuses
|
US7423142B2
(en)
*
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7767802B2
(en)
*
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
DE60232785D1
(de)
|
2001-03-14 |
2009-08-13 |
Myriad Genetics Inc |
Tsg101-gag-wechselwirkung und ihre verwendung
|
AU2002303277A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Vladimir Larionov |
Artificial chromosomes that can shuttle between bacteria, yeast, and mammalian cells
|
AU2002342613A1
(en)
*
|
2001-05-09 |
2002-11-25 |
Geron Corporation |
Treatment for wounds
|
EP1404713A4
(fr)
*
|
2001-05-24 |
2004-09-22 |
Human Dna Technology Inc |
Nouvel analogue du facteur de croissance des keratinocytes-2 du follicule pileux
|
US20070015144A9
(en)
*
|
2001-05-25 |
2007-01-18 |
Genset, S.A. |
Human cDNAs and proteins and uses thereof
|
US7074901B2
(en)
*
|
2001-05-25 |
2006-07-11 |
Serono Genetics Institute S.A. |
Isolated human vCOL16A1 polypeptide and fragments thereof
|
US20030095952A1
(en)
*
|
2001-06-13 |
2003-05-22 |
Krause Diane S. |
Multi-organ engraftment with a single bone marrow-derived stem cell
|
ES2184623B1
(es)
*
|
2001-06-29 |
2004-09-16 |
Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (C.I.E.M.A.T.) |
Piel artificial autologa secretora de leptina y metodo de obtencion.
|
KR20040022449A
(ko)
|
2001-07-12 |
2004-03-12 |
유니버시티 오브 매사추세츠 |
유전자 불활성화를 매개하는 소형 간섭 rna의 생체내제조
|
EP1900815B1
(fr)
|
2001-07-12 |
2016-09-07 |
University of Massachusetts |
Production in vivo de petits ARN interférents qui modèrent le silençage génique
|
WO2003015800A1
(fr)
|
2001-08-09 |
2003-02-27 |
Ivoclar Vivadent, Inc. |
Implants tissulaires et leurs procedes de fabrication et d'utilisation
|
EP1429650B1
(fr)
*
|
2001-08-30 |
2009-06-24 |
Mount Sinai School of Medicine of New York University |
Facteur tissulaire circulant presentant un epissage alternatif
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
JP2005504085A
(ja)
*
|
2001-09-28 |
2005-02-10 |
エスペリオン セラピューティクス,インコーポレイテッド |
薬剤の局所投与による再狭窄の予防および治療
|
AU2002343475A1
(en)
*
|
2001-10-03 |
2003-04-14 |
Selective Genetics, Inc. |
Traversal of nucleic acid molecules through a fluid space and expression in repair cells
|
WO2003029430A2
(fr)
*
|
2001-10-04 |
2003-04-10 |
The Government Of The United States Of America, As |
Sequences de marqueurs repetees en tandem
|
US7745418B2
(en)
*
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
CA2466861A1
(fr)
*
|
2001-11-06 |
2003-07-10 |
Agilix Corporation |
Systemes de detection codes sensibles
|
US7255874B1
(en)
|
2001-12-21 |
2007-08-14 |
Closure Medical Corporation |
Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
WO2003062404A1
(fr)
|
2002-01-25 |
2003-07-31 |
Gamida-Cell Ltd. |
Methodes de developpement de cellules souches et de cellules precurseurs, populations de cellules multipliees obtenues a l'aide de ces methodes
|
US6939554B2
(en)
*
|
2002-02-05 |
2005-09-06 |
Michigan Biotechnology Institute |
Antimicrobial polymer
|
GB2399020B
(en)
*
|
2002-02-14 |
2005-01-12 |
Photogenesis Inc |
Subretinal implantation device and surgical cannulas for use therewith
|
US20060035810A1
(en)
*
|
2002-03-18 |
2006-02-16 |
Shears Stephen B |
Regulation of ins(3456)p4 signalling by a reversible kinase phosphatase and methods and compositions related thereto
|
US7317087B2
(en)
*
|
2002-03-25 |
2008-01-08 |
The Uab Research Foundation |
Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof
|
BR0310100A
(pt)
*
|
2002-05-17 |
2007-04-27 |
Esperion Therapeutics Inc |
métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
|
US6943021B2
(en)
*
|
2002-06-07 |
2005-09-13 |
Mattek Corporation |
Three dimensional vaginal tissue model containing immune cells
|
US7208467B2
(en)
|
2002-06-07 |
2007-04-24 |
Monty Krieger |
Lipid-altering compositions for the treatment of infertility
|
US8271778B1
(en)
|
2002-07-24 |
2012-09-18 |
The Nielsen Company (Us), Llc |
System and method for monitoring secure data on a network
|
CA2421269A1
(fr)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methodes et compositions pour prolonger la duree de vie et accroitre la resistance au stress de cellules et d'organismes
|
JP2006500030A
(ja)
*
|
2002-09-20 |
2006-01-05 |
イェール ユニバーシティ |
リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
|
CA2501940A1
(fr)
*
|
2002-10-09 |
2004-04-22 |
Tolerrx, Inc. |
Molecules preferablement associees aux cellules t effectrices ou aux cellules t regulatrices et procedes d'utilisation de ces molecules
|
US9233120B2
(en)
|
2002-11-15 |
2016-01-12 |
Jyant Technologies |
Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
|
JP4915980B2
(ja)
|
2002-11-15 |
2012-04-11 |
エムユーエスシー ファウンデーション フォー リサーチ デベロップメント |
補体レセプター2標的化補体調節因子
|
US8512701B2
(en)
|
2002-11-15 |
2013-08-20 |
Morehouse School Of Medicine |
Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
|
US8658377B2
(en)
|
2002-11-15 |
2014-02-25 |
Morehouse School Of Medicine |
Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
|
EP1572976B1
(fr)
|
2002-11-21 |
2010-09-15 |
Celltech R & D, Inc. |
Modulation de reponses immunitaires
|
US7803365B2
(en)
*
|
2002-12-02 |
2010-09-28 |
Biovec, Llc |
Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
|
US9388427B2
(en)
*
|
2002-12-02 |
2016-07-12 |
Biovec, Llc |
In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
|
EP2561887B8
(fr)
|
2003-01-14 |
2016-12-21 |
Dana-Farber Cancer Institute, Inc. |
Sensibilisateur de thérapie anticancéreuse
|
DE10302421A1
(de)
*
|
2003-01-21 |
2004-07-29 |
Ribopharma Ag |
Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
|
GB2413799A
(en)
*
|
2003-02-25 |
2005-11-09 |
Biovec B V |
Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
|
US7598287B2
(en)
|
2003-04-01 |
2009-10-06 |
Medical College Of Georgia Research Institute, Inc. |
Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
|
US20050186289A1
(en)
*
|
2003-04-01 |
2005-08-25 |
Medical College Of Georgia Research Institute, Inc. |
Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
|
US7709207B2
(en)
|
2003-05-16 |
2010-05-04 |
Universite Laval |
Method for identifying compounds for treatment of pain
|
ES2357116T5
(es)
|
2003-06-02 |
2021-09-03 |
Univ Massachusetts |
Métodos y composiciones para mejorar la eficacia y especificad de FNAi
|
DK1633767T3
(en)
|
2003-06-02 |
2019-03-25 |
Univ Massachusetts |
METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING
|
BRPI0411243A
(pt)
|
2003-06-10 |
2006-07-11 |
Nsgene As |
método de produzir um polipeptìdio de neublastina biologicamente ativo, ácido nucléico, vetor de expressão, composição farmacêutica, célula, linha de células de compactação, mamìfero não-humano transgênico, dispositivo de cultura de células implantável, uso do vetor, método de tratar uma doença do sistema nervoso, e, polipetìdio de neublastina
|
US7576052B2
(en)
|
2003-10-17 |
2009-08-18 |
Joslin Diabetes Center, Inc. |
Methods and compositions for modulating adipocyte function
|
BRPI0415563A
(pt)
|
2003-10-20 |
2007-01-02 |
Nsgene As |
método para o tratamento do mal de parkinson, uso de um vetor viral, vetor de expressão viral, composição farmacêutica, célula hospedeira isolada, linhagem de células de empacotamento, mamìfero não humano quimérico, dispositivo de cultura celular implantável, cápsula biocompatìvel, método para tratamento de uma doença do sistema nervoso, célula de mamìfero, e, método para produzir neurturin ou um seu equivalente funcional
|
EP1918000A2
(fr)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires
|
US7670771B2
(en)
|
2004-01-21 |
2010-03-02 |
University Of Utah Research Foundation |
Mutant sodium channel Nav1.7 nucleic acid methods
|
US20050272678A1
(en)
*
|
2004-02-11 |
2005-12-08 |
Bodine Peter Van N |
BMP-6 estrogen responsive element and methods of use thereof
|
WO2005086934A2
(fr)
*
|
2004-03-10 |
2005-09-22 |
Board Of Regents, The University Of Texas System |
Banques d'expression d'adnc enrichies et procedes de construction et d'utilisation correspondants
|
AU2005222902B2
(en)
|
2004-03-12 |
2010-06-10 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
WO2005095450A2
(fr)
|
2004-03-30 |
2005-10-13 |
Nsgene A/S |
Utilisation therapeutique d'un facteur de croissance, nsg33
|
EP1732383A4
(fr)
*
|
2004-04-06 |
2007-05-02 |
Cedars Sinai Medical Center |
Prevention et traitement des maladies vasculaires avec des vecteurs de virus associes aux adenovirus de recombinaison codant l'apolipoproteine a-i et l'apolipoproteine a-i milano
|
DK1773872T3
(en)
|
2004-05-21 |
2017-05-08 |
Uab Res Found |
VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
|
US20060021075A1
(en)
*
|
2004-07-15 |
2006-01-26 |
Chyung-Ru Wang |
Group 1 CD1 transgenic mice and their uses
|
WO2006013462A2
(fr)
*
|
2004-07-30 |
2006-02-09 |
Nsgene A/S |
Facteurs de croissance nsg28, nsg30, et nsg32
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
US20060063187A1
(en)
*
|
2004-09-15 |
2006-03-23 |
Hotamisligil Gokhan S |
Modulation of XBP-1 activity for treatment of metabolic disorders
|
EP1799812A4
(fr)
|
2004-09-16 |
2009-09-09 |
Gamida Cell Ltd |
Méthodes de culture ex vivo de cellules souches et de précurseur par co-culture avec des cellules mésenchymales
|
US20080131433A1
(en)
*
|
2004-09-27 |
2008-06-05 |
The Uab Research Foundation |
Fc Receptor Homolog Antibodies And Uses Thereof
|
EP2374469A3
(fr)
|
2004-12-21 |
2012-01-25 |
MUSC Foundation For Research Development |
Compositions et procédés pour la promotion de la cicatrisation de plaies et de la régénération de tissus
|
EP1851551A2
(fr)
*
|
2005-02-03 |
2007-11-07 |
Perkinelmer Las, Inc. |
Systemes de detection ultrasensible utilisant des signaux multidimensionnels
|
WO2006089095A2
(fr)
|
2005-02-17 |
2006-08-24 |
Biogen Idec Ma Inc. |
Traitement de troubles neurologiques
|
CA2625349A1
(fr)
*
|
2005-10-06 |
2007-04-19 |
Emthrax, Llc |
Methodes et compositions en rapport avec l'utilisation de glycoproteines de spores de b. anthracis comme vaccins
|
EP2392647A1
(fr)
|
2005-10-14 |
2011-12-07 |
MUSC Foundation For Research Development |
Ciblage du PAX2 pour l'induction de l'immunité à la tumeur à médiation DEFB1 et le traitement contre le cancer
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
JP4929288B2
(ja)
*
|
2005-11-04 |
2012-05-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Nav1.8遺伝子の発現を抑制するための組成物および方法
|
US20100069461A1
(en)
|
2005-11-09 |
2010-03-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
JP5184367B2
(ja)
|
2005-11-18 |
2013-04-17 |
グレンマーク・ファーマシューティカルズ・エスエー |
抗アルファ2インテグリン抗体およびその使用
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
US8313901B2
(en)
*
|
2005-12-21 |
2012-11-20 |
Yale University |
Methods and compositions related to the modulation of riboswitches
|
TWI515007B
(zh)
*
|
2006-01-05 |
2016-01-01 |
美國猶他大學研究基金會 |
改善以神經系統為標的之藥劑之性質之方法及組合物
|
US8470965B2
(en)
*
|
2006-03-01 |
2013-06-25 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
US9365622B2
(en)
*
|
2006-03-01 |
2016-06-14 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
CA2647728C
(fr)
|
2006-03-31 |
2014-12-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions et methodes destinees a inhiber l'expression du gene eg5
|
EP2013222B1
(fr)
*
|
2006-04-28 |
2013-02-13 |
Alnylam Pharmaceuticals Inc. |
Compositions et procédés d'inhibition de l'expression d'un gène du virus jc
|
EP2835429B1
(fr)
|
2006-05-11 |
2017-12-13 |
Alnylam Pharmaceuticals Inc. |
Compositions et procédés d'inhibition d'expression du gène PCSK9
|
EP2023937B1
(fr)
|
2006-05-19 |
2011-10-12 |
Alnylam Pharmaceuticals Inc. |
Modulation d'aha par l'arn et utilisateurs thérapeutiques de celle-ci
|
US7888498B2
(en)
*
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
BRPI0712607A8
(pt)
|
2006-05-25 |
2019-06-04 |
Biogen Idec Inc |
métodos de tratamento de acidente vascular cerebral
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
EP2377953A1
(fr)
|
2006-06-23 |
2011-10-19 |
Myriad Genetics, Inc. |
Variantes du gène DPYD et leur utilisation
|
JP2010502752A
(ja)
*
|
2006-09-11 |
2010-01-28 |
イェール ユニバーシティー |
リシンリボスイッチ、リシンリボスイッチを用いた構造に基づく化合物設計、ならびにリシンリボスイッチを用いた使用のための方法および組成物
|
EP2560001B1
(fr)
|
2006-09-21 |
2016-04-13 |
University of Rochester |
Compositions et procédés associés à une thérapie par glissement de protéines pour la dystrophie myotonique
|
JP2010512327A
(ja)
|
2006-12-11 |
2010-04-22 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
病的血管形成および脈管透過性の処置用の組成物および方法
|
EP2101567A4
(fr)
|
2007-01-18 |
2010-04-21 |
Univ Utah Res Found |
Compositions et procédés pour détecter, traiter ou prévenir le stress réductif
|
WO2008092041A2
(fr)
|
2007-01-24 |
2008-07-31 |
Carnegie Mellon University |
Biocapteurs optiques
|
US8097588B2
(en)
*
|
2007-02-08 |
2012-01-17 |
Sanford-Burnham Medical Research Institute |
Trophinin-binding peptides and uses thereof
|
EP2471925A1
(fr)
|
2007-03-22 |
2012-07-04 |
Yale University |
Procédés et compositions associés à des riborégulateurs commandant un épissage alterné
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
EP2478766A3
(fr)
|
2007-05-09 |
2012-08-15 |
Burnham Institute for Medical Research |
Ciblage de protéinases hôtes en tant que stratégie thérapeutique contre des pathogènes viraux et bactériens
|
CA2688575A1
(fr)
|
2007-05-29 |
2008-12-24 |
Yale University |
Riboregulateurs et procedes et composition pour l'utilisation de et avec des riboregulateurs
|
CN101688251A
(zh)
*
|
2007-05-29 |
2010-03-31 |
耶鲁大学 |
与控制可变剪接和rna加工的核糖开关有关的方法和组合物
|
EA201000085A1
(ru)
|
2007-07-05 |
2010-10-29 |
Новартис Аг |
dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
|
AU2008296478B9
(en)
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
EP2195340A4
(fr)
|
2007-08-28 |
2011-05-11 |
Uab Research Foundation |
Polypeptides synthétiques analogues d'apolipoprotéine e et procédés d'utilisation
|
WO2009039442A1
(fr)
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia dans la détermination de la destinée gliale, thérapie du gliome et traitement de l'astrocytome
|
PL2222697T3
(pl)
|
2007-11-01 |
2013-05-31 |
Astellas Pharma Inc |
Immunosupresyjne polipeptydy i kwasy nukleinowe
|
CA2706317C
(fr)
*
|
2007-12-03 |
2017-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions de doc1 et methodes de traitement du cancer.
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
EA201301171A1
(ru)
*
|
2008-03-05 |
2014-10-30 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии генов eg5 и vegf
|
US20090233993A1
(en)
*
|
2008-03-06 |
2009-09-17 |
Burnham Institute For Medical Research |
Compositions and methods for inhibiting gsk3 activity and uses thereof
|
AU2009244308A1
(en)
|
2008-05-06 |
2009-11-12 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
US8946291B2
(en)
|
2008-08-15 |
2015-02-03 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for treating pigmentary conditions and melanoma
|
EP2690175B1
(fr)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition combinée d'expression du gène mutant EGFR et IL-6
|
EP3584320A1
(fr)
|
2008-09-25 |
2019-12-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions formulées de lipides et procédés pour inhiber l'expression du gène du sérum amyloïde a
|
DK2344639T3
(en)
|
2008-10-20 |
2015-07-27 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETINE
|
SI2894165T1
(sl)
|
2008-11-10 |
2023-04-28 |
Alexion Pharmaceuticals, Inc. |
Postopki in sestavki za zdravljenje motenj povezanih s komplementom
|
WO2010065617A1
(fr)
|
2008-12-02 |
2010-06-10 |
University Of Utah Research Foundation |
Pde1 en tant que cible thérapeutique dans les maladies cardiaques
|
AU2009324534B2
(en)
|
2008-12-10 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
EP2389191A2
(fr)
|
2009-01-23 |
2011-11-30 |
NsGene A/S |
Expression des neuropeptides dans les cellules des mammiféres
|
CA2753438A1
(fr)
|
2009-02-24 |
2010-09-02 |
Alexion Pharmaceuticals, Inc. |
Anticorps contenant des peptides therapeutiques mimetiques de tpo/epo
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
CN104922699B
(zh)
|
2009-03-12 |
2020-07-24 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
|
EP2408904B1
(fr)
|
2009-03-20 |
2017-10-18 |
Mesoblast, Inc. |
Production de cellules pluripotentes reprogrammées
|
WO2010132665A1
(fr)
|
2009-05-15 |
2010-11-18 |
Yale University |
Riborégulateurs gemm, conception, sur une base structurelle, d'un composé comprenant des riborégulateurs gemm et procédés et compositions utilisables avec des riborégulateurs gemm et permettant de les utiliser
|
US9149024B2
(en)
|
2009-06-22 |
2015-10-06 |
Massachusetts Eye & Ear Infirmary |
Islet1 (Isl1) and hearing loss
|
CA2793835C
(fr)
|
2009-10-21 |
2021-07-20 |
Agios Pharmaceuticals, Inc. |
Procedes et compositions pour des troubles relatifs
|
JP5894535B2
(ja)
|
2009-11-09 |
2016-03-30 |
ジーンポッド セラピューティクス アーベーGenepod Therapeutics Ab |
invivoでのニューロン特異的な最適化された連続DOPA合成用の新規ウイルスベクター構築物
|
US20120321647A1
(en)
|
2010-01-12 |
2012-12-20 |
Yale University |
Structured rna motifs and compounds and methods for their use
|
BR112012017483A2
(pt)
|
2010-01-14 |
2019-09-24 |
Haplomics Inc |
previsão e redução de aloimunogenicidade de terapêuticos de proteína
|
US9745589B2
(en)
|
2010-01-14 |
2017-08-29 |
Cornell University |
Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
|
ES2893199T3
(es)
|
2010-03-29 |
2022-02-08 |
Alnylam Pharmaceuticals Inc |
Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR)
|
NZ603226A
(en)
|
2010-04-30 |
2015-02-27 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
WO2012041328A1
(fr)
|
2010-10-01 |
2012-04-05 |
Nsgene A/S |
Traitement de l'allodynie, de l'hyperalgésie, de la douleur spontanée et de la douleur illusionnelle
|
WO2012051301A1
(fr)
|
2010-10-12 |
2012-04-19 |
President And Fellows Of Harvard College |
Procédés pour identifier des modulateurs du métabolisme des triglycérides, pour moduler le métabolisme des triglycérides et pour identifier des sujets à risque pour le métabolisme anormal des triglycérides
|
US8815942B2
(en)
|
2010-10-20 |
2014-08-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
|
CN106177930A
(zh)
|
2010-12-14 |
2016-12-07 |
吉安特科技股份有限公司 |
抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
|
CN103517712A
(zh)
|
2010-12-15 |
2014-01-15 |
神经佐剂股份有限公司 |
神经肽类似物、组合物和治疗疼痛的方法
|
EP2659271A4
(fr)
|
2010-12-27 |
2015-04-08 |
Univ Brown |
Méthodes thérapeutiques et diagnostiques impliquant le biglycane et l'utrophine
|
WO2012094511A2
(fr)
|
2011-01-05 |
2012-07-12 |
Rhode Island Hospital |
Compositions et procédés destinés au traitement de lésion ou de maladie orthopédique
|
US9956236B2
(en)
|
2011-02-07 |
2018-05-01 |
Cornell University |
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
|
EP2717909B1
(fr)
|
2011-06-04 |
2017-12-06 |
Rochester General Hospital Research Institute |
Compositions et procédés associés à la protéine p6 de l'haemophilus influenzae
|
EP2723351B1
(fr)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition de l'expression de gènes de protéine c (proc)
|
KR20230084331A
(ko)
|
2011-06-21 |
2023-06-12 |
알닐람 파마슈티칼스 인코포레이티드 |
아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
|
US9474786B2
(en)
|
2011-09-05 |
2016-10-25 |
Nsgene A/S |
Treatment of allodynia
|
BR112014020119A2
(pt)
|
2012-02-13 |
2020-10-27 |
Gamida-Cell Ltd |
cultura de células-tronco mesenquimais
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
EP2877214B1
(fr)
|
2012-07-26 |
2019-04-24 |
Joslin Diabetes Center, Inc. |
Prédiction de complications diabétiques
|
WO2014113540A1
(fr)
|
2013-01-16 |
2014-07-24 |
Iowa State University Research Foundation, Inc. |
Cible intronique profonde pour la correction d'épissure sur le gène de l'amyotrophie spinale (sma)
|
US20160002316A1
(en)
|
2013-02-22 |
2016-01-07 |
Joslin Diabetes Center |
Serpins: methods of therapeutic beta-cell regeneration and function
|
EP2851086A1
(fr)
|
2013-09-20 |
2015-03-25 |
Sanofi |
Serpines Procédés de régénération thérapeutique et de fonction des cellules beta
|
EP2769732A1
(fr)
|
2013-02-22 |
2014-08-27 |
Sanofi |
Serpines Procédés de régénération thérapeutique et de fonction des cellules beta
|
WO2014160418A2
(fr)
|
2013-03-13 |
2014-10-02 |
GeneWeave Biosciences, Inc. |
Particules de transduction non réplicative et systèmes rapporteurs à base de particules de transduction
|
US20140379421A1
(en)
|
2013-06-25 |
2014-12-25 |
The Nielsen Company (Us), Llc |
Methods and apparatus to characterize households with media meter data
|
DK3049521T3
(en)
|
2013-09-25 |
2019-04-23 |
Univ Cornell |
Compounds for inducing antitumor immunity and methods thereof
|
WO2015123201A1
(fr)
|
2014-02-11 |
2015-08-20 |
The Nielsen Company (Us), Llc |
Procédés et appareil pour calculer une probabilité de visualisation de vidéo à la demande et de publicité insérée de manière dynamique
|
US10214741B2
(en)
|
2014-02-14 |
2019-02-26 |
University Of Utah Research Foundation |
Methods and compositions for inhibiting retinopathy of prematurity
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
EP3142679A4
(fr)
|
2014-03-25 |
2017-10-11 |
University of Utah Research Foundation |
Inhibiteurs peptidiques de l'oligomérisation de bcr-abl
|
CN107206105A
(zh)
|
2014-07-24 |
2017-09-26 |
麻省眼耳科医院 |
色素性视网膜炎的rpgr基因疗法
|
US10653747B2
(en)
|
2014-07-31 |
2020-05-19 |
Uab Research Foundation |
ApoE mimetic peptides and higher potency to clear plasma cholesterol
|
WO2016118832A1
(fr)
|
2015-01-22 |
2016-07-28 |
University Of Massachusetts |
Immunothérapie anticancéreuse
|
EP3250588A1
(fr)
|
2015-01-29 |
2017-12-06 |
Board of Trustees of Michigan State University |
Polypeptides cryptiques et leurs utilisations
|
SI3265568T1
(sl)
|
2015-03-06 |
2020-10-30 |
Massachusetts Eye & Ear Infirmary |
Terapije za povečanje genov za podedovano degeneracijo mrežnice povzročene z mutacijami PRPF31 gena
|
US10219039B2
(en)
|
2015-03-09 |
2019-02-26 |
The Nielsen Company (Us), Llc |
Methods and apparatus to assign viewers to media meter data
|
WO2016144917A1
(fr)
|
2015-03-10 |
2016-09-15 |
University Of Massachusetts |
Ciblage de gdf6 et de la signalisation médiée par les bmp pour une thérapie contre le mélanome
|
US10723794B2
(en)
|
2015-03-18 |
2020-07-28 |
University Of South Carolina |
Anti-CcL8 antibodies and uses thereof
|
US20180104331A1
(en)
|
2015-05-11 |
2018-04-19 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
EP3294332A4
(fr)
|
2015-05-14 |
2018-12-26 |
Joslin Diabetes Center, Inc. |
Protéine 3 de liaison au rétinol (rbp3) à utiliser en tant que facteur de protection dans la dégénérescence rétinienne non diabétique
|
WO2017021359A1
(fr)
|
2015-08-03 |
2017-02-09 |
Myodopa Limited |
Synthèse et régulation systémiques de la l-dopa
|
US9848224B2
(en)
|
2015-08-27 |
2017-12-19 |
The Nielsen Company(Us), Llc |
Methods and apparatus to estimate demographics of a household
|
WO2017066796A2
(fr)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulateurs de maladies impliquant des télomères
|
WO2017087708A1
(fr)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Hétérodimères dans l'immunité de l'interleukine 12b (p40) de type antigène lymphocytaire cd5 (cd5l)
|
EP3397282A4
(fr)
|
2015-12-30 |
2019-08-07 |
Momenta Pharmaceuticals, Inc. |
Méthodes associées à des produits biologiques
|
WO2017198839A1
(fr)
|
2016-05-20 |
2017-11-23 |
Vihinen Mauno |
Domaines de déstabilisation pour la stabilisation conditionnelle d'une protéine
|
WO2018001858A1
(fr)
|
2016-06-27 |
2018-01-04 |
University Of Copenhagen |
Assemblage sur mesure d'un polypeptide modulaire de bourgeon
|
US11459568B2
(en)
|
2016-10-31 |
2022-10-04 |
University Of Massachusetts |
Targeting microRNA-101-3p in cancer therapy
|
US10791355B2
(en)
|
2016-12-20 |
2020-09-29 |
The Nielsen Company (Us), Llc |
Methods and apparatus to determine probabilistic media viewing metrics
|
WO2018191599A1
(fr)
|
2017-04-14 |
2018-10-18 |
University Of Massachusetts |
Adipokines sélectives vis-à-vis de la graisse brune
|
JP7401312B2
(ja)
|
2017-06-28 |
2023-12-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ヒトパピローマウイルス(hpv)抗原結合性タンパク質およびその使用方法
|
DK3658184T3
(da)
|
2017-07-27 |
2023-11-27 |
Alexion Pharma Inc |
Højkoncentrerede anti-c5-antistofformuleringer
|
WO2019055618A1
(fr)
|
2017-09-15 |
2019-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Procédés de classification des réponses à une immunothérapie anticancéreuse
|
AU2018351053A1
(en)
|
2017-10-18 |
2020-05-07 |
Washington University |
Dominant negative sarm1 molecules as a therapeutic strategy for neurodegenerative diseases or disorders
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
BR112020024179A2
(pt)
|
2018-06-01 |
2021-03-30 |
Sanofi |
Terapia de combinação para tratar infecção por vírus da hepatite b
|
WO2020018825A1
(fr)
|
2018-07-19 |
2020-01-23 |
Regeneron Pharmaceuticals, Inc. |
Récepteurs antigéniques chimériques possédant une spécificité pour le bcma, et utilisations correspondantes
|
EA202191107A1
(ru)
|
2018-10-23 |
2021-09-17 |
Ридженерон Фармасьютикалз, Инк. |
T-клеточные рецепторы ny-eso-1 и способы их применения
|
WO2020120649A1
(fr)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cellules présentatrices d'antigène artificiel qui expriment de manière constitutive un antigène conjointement avec une molécule hla de classe ii
|
WO2020136154A1
(fr)
|
2018-12-27 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Particules transductrices non réplicatives et systèmes rapporteurs à base de particules transductrices pour la détection d'acinetobacter baumannii
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
IT201900007060A1
(it)
|
2019-05-21 |
2020-11-21 |
St Superiore Di Sanita |
Cellule tumorali ingegnerizzate e loro usi
|
IT201900012540A1
(it)
|
2019-07-22 |
2021-01-22 |
Humanitas Mirasole Spa |
Inibitori di CHI3L1 e loro usi
|
CN114174345A
(zh)
|
2019-07-24 |
2022-03-11 |
瑞泽恩制药公司 |
具有mage-a4特异性的嵌合抗原受体和其用途
|
WO2021067526A1
(fr)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Inhibiteurs du complément pour le traitement d'une réponse médiée par le complément induite par un médicament
|
EP4038222A4
(fr)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
Procédés et compositions pour identifier des néo-antigènes destinés à être utilisés dans le traitement et la prévention du cancer
|
US20230242655A1
(en)
|
2019-12-03 |
2023-08-03 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins and uses thereof
|
WO2021110561A1
(fr)
|
2019-12-03 |
2021-06-10 |
Evotec International Gmbh |
Protéines de liaison à l'antigène associées à l'interféron, destinées à être utilisées dans le traitement d'infection par le virus de l'hépatite b
|
US20220356537A1
(en)
|
2019-12-31 |
2022-11-10 |
Roche Molecular Systems, Inc. |
Quantitative pcr screening of inducible prophage from bacterial isolates
|
MX2022009137A
(es)
|
2020-01-24 |
2022-10-21 |
Regeneron Pharma |
Antígeno expresado preferentemente en receptores de linfocitos t de melanoma (prame) y sus métodos de uso.
|
WO2021217024A1
(fr)
|
2020-04-24 |
2021-10-28 |
Millennium Pharmaceuticals, Inc. |
Anticorps anti-cd19 et leurs utilisations
|
MX2022013898A
(es)
|
2020-05-05 |
2023-02-09 |
Regeneron Pharma |
Car que comprende cd28 zeta y cd3 zeta.
|
CN116615443A
(zh)
|
2020-09-14 |
2023-08-18 |
Vor生物制药股份有限公司 |
针对cd33的单结构域抗体
|
IL303741A
(en)
|
2020-12-18 |
2023-08-01 |
Momenta Pharmaceuticals Inc |
Antibodies against integrin alpha 11 in cell 1
|
EP4267236A2
(fr)
|
2020-12-24 |
2023-11-01 |
Novocure GmbH |
Méthodes et compositions pour utiliser des champs électriques alternatifs en thérapie génique
|
EP4320149A1
(fr)
|
2021-04-09 |
2024-02-14 |
Takeda Pharmaceutical Company Limited |
Anticorps ciblant le facteur d du complément et leurs utilisations
|
CA3216770A1
(fr)
|
2021-04-26 |
2022-11-03 |
Tomoki Yoshihara |
Anticorps anti-clec12a et leurs utilisations
|
CA3214355A1
(fr)
|
2021-04-26 |
2022-11-03 |
Antara Banerjee |
Anticorps anti-adgre2 et leurs utilisations
|
CA3217914A1
(fr)
|
2021-05-04 |
2022-11-10 |
Kevin BRAY |
Recepteurs antigeniques chimeriques presentant une specificite pour mage-a4 et utilisations associees
|
WO2022233989A1
(fr)
|
2021-05-06 |
2022-11-10 |
Hoba Therapeutics Aps |
Prévention et traitement de la douleur neuropathique induite par une chimiothérapie
|
CA3220925A1
(fr)
|
2021-06-09 |
2022-12-15 |
Kara Carter |
Proteines de liaison a l'antigene associees a l'interferon destinees a etre utilisees pour le traitement ou la prevention d'une infection a coronavirus
|
AR127408A1
(es)
|
2021-10-20 |
2024-01-17 |
Takeda Pharmaceuticals Co |
Composiciones dirigidas a bcma y métodos de uso de las mismas
|
WO2023104960A1
(fr)
|
2021-12-10 |
2023-06-15 |
Hoba Therapeutics Aps |
Traitement de la douleur nociceptive
|
WO2023201238A1
(fr)
|
2022-04-11 |
2023-10-19 |
Vor Biopharma Inc. |
Agents de liaison et leurs méthodes d'utilisation
|
WO2023240109A1
(fr)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Molécules multispécifiques pour moduler l'activité des lymphocytes t, et leurs utilisations
|
WO2024091669A1
(fr)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Récepteurs antigéniques chimériques comprenant une paire de domaines intracellulaires
|